Safety of Intravenous Milrinone for the Treatment of Subarachnoid Hemorrhage-induced Vasospasm

CompletedOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2020

Primary Completion Date

August 31, 2020

Study Completion Date

August 31, 2020

Conditions
Cerebral VasospasmSubarachnoid Hemorrhage
Interventions
OTHER

Rhythmic tolerance

Rhythmic intolerance is defined by the occurrence of arrhythmia prompting the initiation of an antiarrhythmic medication and the need to decrease or even to stop the infusion of milrinone

OTHER

Hematological tolerance

Hematological tolerance will be considered good if milrinone infusion was not interrupted owing to the occurrence of thrombocytopenia

OTHER

Milrinone efficiency on cerebral vasospasm

It will be assessed using ultrasound measurements of middle cerebral arteries velocities. A decrease of at least 20% of the mean velocity or of the Lindegaard index will be considered as a significant positive effect of the treatment (including milrinone).

OTHER

Milrinone efficiency using the modified Rankin scale

Scored as follows: 0 = No symptoms, 1 = No significant disability. Able to perform all usual activities, despite certain symptoms, 2= Slight disability. Able to take care of his own affairs without assistance, but unable to carry out all previous activities, 3 = Moderate disability. Requires some help, but able to walk unassisted, 4 = Moderate severe disability. Unable to meet their own physical needs without help and unable to walk without help, 5 Severe disability. Needs constant care and attention, bedridden, incontinent, 6 = Death.

Trial Locations (1)

44000

CHU Nantes, Nantes

All Listed Sponsors
lead

Nantes University Hospital

OTHER

NCT03517670 - Safety of Intravenous Milrinone for the Treatment of Subarachnoid Hemorrhage-induced Vasospasm | Biotech Hunter | Biotech Hunter